Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Monday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

Several other equities research analysts also recently weighed in on COYA. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Tuesday, May 13th. D. Boral Capital restated a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, April 22nd. Finally, Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Coya Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Coya Therapeutics Stock Performance

Shares of NASDAQ:COYA opened at $5.88 on Monday. Coya Therapeutics has a one year low of $4.65 and a one year high of $10.24. The stock has a market capitalization of $98.34 million, a price-to-earnings ratio of -9.05 and a beta of 0.21. The company has a 50-day simple moving average of $5.78 and a 200-day simple moving average of $6.05.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $257.88 million during the quarter, compared to analyst estimates of $2.63 million. As a group, research analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of large investors have recently made changes to their positions in the stock. Newbridge Financial Services Group Inc. acquired a new position in Coya Therapeutics during the fourth quarter worth about $401,000. Tower Research Capital LLC TRC boosted its stake in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after acquiring an additional 4,777 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Coya Therapeutics in the 4th quarter worth approximately $74,000. Northern Trust Corp increased its stake in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after purchasing an additional 3,099 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Coya Therapeutics by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after purchasing an additional 8,267 shares in the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.